Trial · NCT00082017
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Complete response | 18 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Complete response | 0 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Complete response unconfirmed | 0 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Complete response unconfirmed | 0 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Partial response | 9 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Partial response | 0 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Progressive disease | 55 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Progressive disease | 45 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Stable disease | 9 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Stable disease | 33 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | Not evaluable | 9 | Percentage of participants | |
| Clinical Response Rate | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | Not evaluable | 22 | Percentage of participants | |
| Progression Free Survival (PFS) | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | 0.8 | 95% Confidence Interval 0.2 to 2.2 | months | |
| Progression Free Survival (PFS) | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | 0.8 | 95% Confidence Interval 0.4 to 3.6 | months | |
| Overall Survival (OS) | UCN-01 for T-cell Lymphomas - Cohort 1 Every 28 Days | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | UCN-01 for T-cell Lymphomas - Cohort 2 Every 21 Days | 5.2 | 95% Confidence Interval 0.7 to 55.0 | months | |
| Number of Participants With Adverse Events | UCN-01 for T-cell Lymphomas - Cohort 1&2 | 19 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00082017/results